These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9463298)

  • 1. [Ofloxacin in mycobacteriosis therapy].
    Padełskaya EN
    Antibiot Khimioter; 1997; 42(11):26-31. PubMed ID: 9463298
    [No Abstract]   [Full Text] [Related]  

  • 2. [Value of ciprofloxacin in the therapy of tuberculosis and other mycobacterioses].
    Padeĭskaia EN
    Antibiot Khimioter; 1997; 42(6):15-25. PubMed ID: 9313055
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic prospects for paucibacillary leprosy.
    Katoch K
    Indian J Lepr; 2000; 72(3):351-61. PubMed ID: 11105276
    [No Abstract]   [Full Text] [Related]  

  • 4. [Can ofloxacin constitute an alternative antitubercular treatment for BCG hepatitis?].
    Fendler JP; Debois H; Mége JL; Kepenekian G
    Prog Urol; 2002 Apr; 12(2):309-12. PubMed ID: 12108350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of sparfloxacin against Mycobacterium leprae measured by the proportional bactericidal test.
    McDermott-Lancaster RD; Banerjee DK
    Int J Lepr Other Mycobact Dis; 1993 Dec; 61(4):605-8. PubMed ID: 8151193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial activity of ofloxacin and other agents against mycobacterial isolates from postoperative sternotomy wounds.
    Yew WW; Kwan SY; Ma WK; Lui KS; Aung MK
    Clin Ther; 1989; 11(6):775-85. PubMed ID: 2611821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The rapid development of fluoroquinolone resistance in M. tuberculosis.
    Ginsburg AS; Woolwine SC; Hooper N; Benjamin WH; Bishai WR; Dorman SE; Sterling TR
    N Engl J Med; 2003 Nov; 349(20):1977-8. PubMed ID: 14614180
    [No Abstract]   [Full Text] [Related]  

  • 8. [Comparison of in-vitro and in-vivo activities of enoxacin and ofloxacin against the Mycobacterium tuberculosis].
    Xu G; Li H; Liu S
    Zhonghua Jie He He Hu Xi Za Zhi; 1995 Jun; 18(3):175-7, 192. PubMed ID: 8565090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of the new quinolones in the treatment and prevention of tuberculosis and other infections caused by mycobacterium].
    Ciruelos E; Zalazaín R; Sobradillo V
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():34-8. PubMed ID: 10563109
    [No Abstract]   [Full Text] [Related]  

  • 10. Pacemaker infections due to rapidly growing mycobacteria: further experience.
    Tam WO; Yew WW; Yam WC; Yuen KY; Wong PC; Tse TF
    Int J Tuberc Lung Dis; 2007 Jan; 11(1):118. PubMed ID: 17217143
    [No Abstract]   [Full Text] [Related]  

  • 11. [In vitro and in vivo activities of norfloxacin, ofloxacin and ciprofloxacin against various mycobacteria].
    Saito H; Sato K; Tomioka H; Watanabe T
    Kekkaku; 1987 May; 62(5):287-94. PubMed ID: 3114537
    [No Abstract]   [Full Text] [Related]  

  • 12. Mycobacteria and the new quinolones.
    Leysen DC; Haemers A; Pattyn SR
    Antimicrob Agents Chemother; 1989 Jan; 33(1):1-5. PubMed ID: 2540705
    [No Abstract]   [Full Text] [Related]  

  • 13. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines.
    Grimaldo ER; Tupasi TE; Rivera AB; Quelapio MI; Cardaño RC; Derilo JO; Belen VA
    Int J Tuberc Lung Dis; 2001 Jun; 5(6):546-50. PubMed ID: 11409582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination chemotherapy of drug-resistant tuberculosis with inclusion of ofloxacin (zanocin)].
    Padeĭskaia EN
    Antibiot Khimioter; 2001; 46(8):9-18. PubMed ID: 11871320
    [No Abstract]   [Full Text] [Related]  

  • 15. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
    Tomioka H
    Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active leprosy treated effectively with ofloxacin.
    Mochizuki Y; Oishi M; Nishiyama C; Iida T
    Intern Med; 1996 Sep; 35(9):749-51. PubMed ID: 8915706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo activity of ciprofloxacin, ofloxacin, norfloxacin and pipemidic acid against Escherichia coli infections in mice.
    Obana Y; Nishino T
    Drugs Exp Clin Res; 1989; 15(2):53-8. PubMed ID: 2661182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ofloxacin combined with Lactobacillus casei against Mycobacterium fortuitum infection induced in mice.
    Tomioka H; Sato K; Saito H
    Antimicrob Agents Chemother; 1990 Apr; 34(4):632-6. PubMed ID: 2344170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Usefulness of levofloxacin in sinusitis].
    Ramos P; Hueto J
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():59-62. PubMed ID: 10563114
    [No Abstract]   [Full Text] [Related]  

  • 20. [Levofloxacin, in vitro activity].
    Perea EJ
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():8-13. PubMed ID: 10563104
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.